Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

Moderna raised its sales outlook after Q3 2026 profit beat estimates

The drugmaker's 2026 revenue growth forecast is 15% to 25%, up from up to 10%; its year-end cash outlook rose to $8.1 billion to $8.3 billion

Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.

Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes

The biopharmaceutical company said it now expects total revenue growth of 15% to 25% for the year, compared with a previous outlook for up to 10% growth.